×
About 19,528 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  6,843 results

Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
https://clinicaltrials.gov/ct2/show/NCT01925196

Jul 1st, 2022 - Objective The primary objective of this study is to characterize the natural history of disease in patients who carry a repeat expansion in the C9ORF72 gene, which causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The s...

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel TSPO Radioligand
https://clinicaltrials.gov/ct2/show/NCT03958630

Jul 1st, 2022 - Objectives The primary objective is to explore if human subjects with neurodegenerative diseases exhibit different level of neuroinflammation, as measured by brain uptake of a 3rd generation [11C]ER176 TSPO ligand, compared to control subjects. Th...

A Study of Monepantel in Individuals With Motor Neurone Disease
https://clinicaltrials.gov/ct2/show/NCT04894240

Jul 1st, 2022 - Amyotrophic lateral sclerosis/ Motor Neurone Disease (ALS/MND) is a rare and invariably fatal neurological disease. ALS/MND has a terribly high burden on patients, family and carers, and carries great socioeconomic burden. Current best treatment o...

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
https://clinicaltrials.gov/ct2/show/NCT03225144

Jul 1st, 2022 - Objectives The primary objective is to evaluate patients referred with a diagnosis of frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or related adult-onset neurodegenerative disorders to assess patient eligibility for ongoing ...

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT02437110

Jul 1st, 2022 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to ...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  538 results

Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
https://clinicaltrials.gov/ct2/show/NCT01925196

Jul 1st, 2022 - Objective The primary objective of this study is to characterize the natural history of disease in patients who carry a repeat expansion in the C9ORF72 gene, which causes amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The s...

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel TSPO Radioligand
https://clinicaltrials.gov/ct2/show/NCT03958630

Jul 1st, 2022 - Objectives The primary objective is to explore if human subjects with neurodegenerative diseases exhibit different level of neuroinflammation, as measured by brain uptake of a 3rd generation [11C]ER176 TSPO ligand, compared to control subjects. Th...

A Study of Monepantel in Individuals With Motor Neurone Disease
https://clinicaltrials.gov/ct2/show/NCT04894240

Jul 1st, 2022 - Amyotrophic lateral sclerosis/ Motor Neurone Disease (ALS/MND) is a rare and invariably fatal neurological disease. ALS/MND has a terribly high burden on patients, family and carers, and carries great socioeconomic burden. Current best treatment o...

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
https://clinicaltrials.gov/ct2/show/NCT03225144

Jul 1st, 2022 - Objectives The primary objective is to evaluate patients referred with a diagnosis of frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), or related adult-onset neurodegenerative disorders to assess patient eligibility for ongoing ...

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT02437110

Jul 1st, 2022 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to ...

see more →

News  395 results

FDA Unveils 5-Year Plan for ALS, Other Neurodegenerative Diseases
https://www.medscape.com/viewarticle/976169

Jun 24th, 2022 - The US Food and Drug Administration (FDA) has unveiled a 5-year strategy aimed at improving and extending the lives of people with rare neurodegenerative diseases. The agency's Action Plan for Rare Neurodegenerative Diseases including Amyotrophic ...

Tofersen linked to slow, positive effects in ALS
https://www.mdedge.com/neurology/article/255728/rare-diseases/tofersen-linked-slow-positive-effects-als
Kate Johnson

Jun 23rd, 2022 - An open-label extension of Biogen’s phase 3 VALOR study shows statistically significant benefits for the company’s novel antisense oligonucleotide (ASO), tofersen, in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase.

Tofersen Linked to Slow but Positive ALS Outcomes
https://www.medscape.com/viewarticle/976134

Jun 23rd, 2022 - An open-label extension of Biogen's phase 3 VALOR study shows statistically significant benefits for the company's novel antisense oligonucleotide (ASO), tofersen, in patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase...

FDA Approves Oral Form of ALS Drug Edaravone
https://www.medscape.com/viewarticle/973926

May 13th, 2022 - The US Food and Drug Administration (FDA) has approved an orally administered version of edaravone (Radicava ORS) for adults with amyotrophic lateral sclerosis (ALS).  Edaravone is a pyrazolone free-radical scavenger thought to lessen the effects ...

Ultra-High Dose Drug Slows Functional Decline in Early ALS, Phase 3 Data Show
https://www.medscape.com/viewarticle/973901

May 12th, 2022 - An ultrahigh-dose of methylcobalamin slows functional decline by 43% in patients with early-stage amyotrophic lateral sclerosis (ALS), new research shows. The 50-mg dose was administered twice-weekly via intramuscular injection. In the phase 3 stu...

see more →

Patient Education  15 results see all →